Current clinical development of PI3K pathway inhibitors in glioblastoma

Neuro-Oncology

Volumn 14, Issue 7, 2012, Pages 819-829

  Wen, Patrick Y ^a,b,d   Lee, Eudocia Q ^a,b,d   Reardon, David A ^a,d   Ligon, Keith L ^a,b,c,d   Alfred Yung, W K ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AKT; GBM; glioblastoma; mTOR; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; BAY 806946; BEVACIZUMAB; BUPARLISIB; BYL 719; EVEROLIMUS; GDC 0980; GSK 2126458; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PF 4691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PICTRELISIB; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP; S6 KINASE; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 765;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BRAIN EDEMA; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CARCINOMA; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG ERUPTION; DRUG TARGETING; EMOTIONAL DISORDER; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENE SILENCING; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MENTAL INSTABILITY; MESOTHELIOMA; MOOD DISORDER; MULTICENTER STUDY (TOPIC); NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CANCER; OVERALL SURVIVAL; PAROTID GLAND CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; VOMITING;

BRAIN NEOPLASMS; DRUG DESIGN; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION;

EID: 84862895654     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos117     Document Type: Review

References (101)

1. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97-117.
2. Central Brain Tumor Registry of the United States. (2011) Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Available at http://cbtrus.org/2007-2008/2007-20081.html. Accessed August 30, 2011.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
5. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res. 2011;17:1674-1683.
6. Blay JY. A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev. 2011;37:373-384.
7. Knobbe CB, Merlo A, Reifenberger G. PTEN signaling in gliomas. Neuro Oncol. 2002;4:196-211.
8. Kanu OO, Hughes B, Di C, et al. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol. 2009;3: 39-52.
9. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131-1138.
10. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
11. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27: 740-745.
12. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296:1655-1657. (Pubitemid 34579158)
13. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075-1083.
14. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550-562.
15. Dugani CB, Klip A. Glucose transporter 4: cycling, compartments and controversies. EMBO Rep. 2005;6:1137-1142. (Pubitemid 41741696)
16. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501. (Pubitemid 37328931)
17. Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 2009;29:5657-5670.
18. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166:213-223. (Pubitemid 38988774)
19. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000;25:55-57. (Pubitemid 30257036)
20. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cellcycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 1998;12:3675-3685. (Pubitemid 29019648)
21. Gallia GL, Rand V, Siu IM, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res. 2006;4: 709-714. (Pubitemid 44683311)
22. Cheng CK, Fan QW, Weiss WA. PI3K signaling in glioma-animal models and therapeutic challenges. Brain Pathol. 2009;19:112-120.
23. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3:1221-1224. (Pubitemid 40268595)
24. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 2004;64:5048-5050. (Pubitemid 39006515)
25. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol. 1992;51:84-90.
26. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA. 1992;89:2965-2969.
27. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024. (Pubitemid 41609094)
28. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
29. Masica DL, Karchin R. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res. 2011;71:4550-4561.
30. Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther. 2008;7:1321-1325.
31. Kita D, Yonekawa Y,Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 2007;113: 295-302. (Pubitemid 46443564)
32. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet. 2008;372:449-456.
33. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-2281. (Pubitemid 46849157)
34. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801-1811.
35. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
36. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23: 5294-5304. (Pubitemid 46206983)
37. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357-361. (Pubitemid 40980358)
38. Sarkaria JN, Galanis E, Wu W, et al. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81:468-475.
39. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5:e8.
40. Voliva CF, Pecchi S, Burger M, et al. Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; Apr 17-21;2010; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr 4498.
41. Maira M, Menezes D, Pecchi S, et al. NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; Apr 17-21; 2010; Washington, DC Philadelphia (PA): AACR; 2010. Abstract nr 4497.
42. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30:282-290.
43. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res. 2012;18:184-195.
44. Grana B, Burris HA, Rodon Ahnert J, et al. Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: an update on safety and efficacy [abstract]. J Clin Oncol. 2011;29:3043.
45. Ihle NT, Lemos R, Schwartz D, et al. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther. 2009;8:94-100.
46. She QB, Chandarlapaty S, Ye Q, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One. 2008;3:e3065.
47. Tabernero J, Rojo F, Calvo E, et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008;26:1603-1610.
48. Cherrin C, Haskell K, Howell B, et al. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther. 2010;9: 493-503.
49. Elizalde VS, Russillo M, Scaltriti M, et al. Dual-targeting of AMPK and PI3K/mTOR in a panel of breast cancer cell lines [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; Apr 17-21 2010; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr 4477.
50. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26:1588-1595.
51. Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27:193-198.
52. Ihle NT, Lemos R, Wipf P, et al. Mutations in the phosphatidylinositol-3- kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69:143-150.
53. Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010;12:559-569.
54. Jimeno A, Herbst RS, Falchook GS, et al. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase [abstract]. J Clin Oncol. 2010;28:3089.
55. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Breast Cancer Special Feature: feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 2012;109:2718-2723.
56. Moldovan C, Soria J, LoRusso P, et al. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol. 2010;28:3070.
57. Traynor AM, Kurzrock R, Bailey HH, et al. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol. 2010; 28:3078.
58. Edelman G, Bedell C, Shapiro G, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies [abstract]. J Clin Oncol. 2010;28:3004.
59. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7: 1851-1863.
60. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68:8022-8030.
61. Konstantinidou G, Bey EA, Rabellino A, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009;69: 7644-7652.
62. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer. 2009;100:1267-1276.
63. De PKR, De N, Leyland-Jones B. In vitro evaluation of dual pan-PI3-kinase/mTOR inhibitor in HER2 overexpressing breast cancer cells [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; Apr 17-21 2010; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr 337.
64. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia. 2010;24:1781-1784.
65. Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther. 2011;11:938-946.
66. Fan QW, Cheng C, Hackett C, et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal. 2010;3:ra81.
67. Liu TJ, Koul D, LaFortune T, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 2009;8:2204-2210.
68. Peyton JD, Rodon Ahnert J, Burris H, et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors [abstract]. J Clin Oncol. 2011;29:3066.
69. Prasad G, Sottero T, Yang X, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011;13:384-392.
70. LoRusso P, Markman B, Tabernero J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors [abstract]. J Clin Oncol. 2009;27:3502.
71. Brana I, LoRusso P, Baselga J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies [abstract]. J Clin Oncol. 2010;28:3030.
72. Cohen RB, Janne PA, Engelman JA, et al. A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors[abstract]. J Clin Oncol. 2010;28:3015.
73. Nghiemphu PL, Omuro AM, Cloughesy T, et al. A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma [abstract]. J Clin Oncol. 2010;28:3085.
74. Dolly S, Wagner AJ, Bendell JC, et al. A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma [abstract]. J Clin Oncol. 2010;28:3079.
75. Wagner AJ, Bendell JC, Dolly S, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors [abstract]. J Clin Oncol. 2011;29:3020.
76. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003;2:1093-1103.
77. Friedman DR, Davis PH, Lanasa MC, et al. Pre-clinical and interim results of a Phase II trial of perifosine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2010;116:1842.
78. Carlo-Stella C, Guidetti A, Viviani S, et al. Clinical activity and safety of the combined therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory lymphomas: preliminary results of a Phase II trial [abstract]. Blood. 2010;116:2861.
79. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010;16:1033-1041.
80. Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007;5: 433-437. (Pubitemid 351219696)
81. Unger C, Berdel W, Hanauske AR, Sindermann H, Engel J, Mross K. First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer. 2010;46: 920-925.
82. Becher OJ, Trippett TM, Kolesar J, et al. Phase I study of single-agent perifosine for recurrent pediatric solid tumors [abstract]. J Clin Oncol. 2010;28:9540.
83. Greco FA, Infante JR, Burris HA, et al. Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol. 2010;28:e14086.
84. Richards DA, Nemunaitis JJ, Vukelja SJ, et al. Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second-or third-line metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol. 2010;28:3531.
85. Campos LT, Nemunaitis J, Stephenson J, et al. Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol. 2009;27:e15505.
86. Vogelzang NJ, Hutson TE, Samlowski W, et al. Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor [abstract]. J Clin Oncol. 2009;27:5034.
87. Bailey HH, Mahoney MR, Ettinger DS, et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer. 2006;107:2462-2467. (Pubitemid 44748530)
88. Momota H, Nerio E, Holland EC. Perifosine inhibitsmultiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 2005;65:7429-7435. (Pubitemid 41161277)
89. Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011;29:4688-4695.
90. Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle. 2008;7:3805-3809.
91. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-1508. (Pubitemid 43259931)
92. Banerji U, Aghajanian C, Raymond E, et al. First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor [abstract]. J Clin Oncol. 2011;29:3096.
93. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120: 2858-2866.
94. Lin JS, Webber EM, Senger CA, Holmes RS, Whitlock EP. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res. 2011;1:650-662.
95. Janku F, Garrido-Laguna I, Wheler JJ, et al. Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTORpathway inhibitors [abstract]. J Clin Oncol. 2011;29:10507.
96. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009;4:e7887.
97. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146-158.
98. Ducray F, De Reynies A, Chinot O, et al. An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Mol Cancer. 2010;9:234.
99. Papadopoulos KP, Markman B, Tabernero J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors [abstract]. J Clin Oncol. 2008;26:3510.
100. Shapiro G, Kwak E, Baselga J, et al. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors [abstract]. J Clin Oncol. 2009;27:3500.
101. Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol. 2010;28:3005.